Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 30 vs AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENa C) in the distal convoluted tubule and collecting duct, inhibiting sodium reabsorption and reducing potassium excretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, increasing sodium, chloride, and water excretion.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Hypertension,Edema associated with congestive heart failure, cirrhosis, or nephrotic syndrome,Hypokalemia prevention or correction in patients on diuretics
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
One tablet (amiloride 5 mg/hydrochlorothiazide 50 mg) orally once daily initially, increased if needed to twice daily. Maximum dose: amiloride 10 mg/hydrochlorothiazide 100 mg daily.
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Amiloride: 6-9 hours (prolonged in renal impairment); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment, heart failure).
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Amiloride is not metabolized; excreted unchanged in urine. Hydrochlorothiazide is not extensively metabolized; small amounts are metabolized hepatically via CYP450 enzymes, but the exact pathways are not well defined.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
Amiloride: 50% unchanged in urine, 40% in feces (biliary); Hydrochlorothiazide: >95% unchanged in urine.
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
Amiloride: ~23%; Hydrochlorothiazide: 40-68% (primarily to albumin).
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
Amiloride: 350-440 L (5-6 L/kg in 70 kg adult), indicating extensive tissue distribution; Hydrochlorothiazide: 3-5 L/kg, distributes into extracellular space.
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
Amiloride: 50-80% (oral); Hydrochlorothiazide: 60-80% (oral).
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
Contraindicated if GFR <30 m L/min or serum creatinine >2.5 mg/d L. For GFR 30-50 m L/min: use with caution and monitor electrolytes; avoid if further renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Child-Pugh Class A: no adjustment; Class B: reduce dose or use alternative; Class C: avoid use (risk of hepatic encephalopathy).
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
Not established; safety and efficacy not determined in children.
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
Start at lowest dose, monitor electrolytes and renal function; increased sensitivity to hypotension and electrolyte disturbances; avoid if creatinine clearance <30 m L/min.
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
None
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Hyperkalemia risk, especially with renal impairment, diabetes, or concomitant use of potassium supplements, ACE inhibitors, or aldosterone antagonists,Electrolyte imbalances (hyponatremia, hypomagnesemia, hypochloremia),Azotemia and renal impairment,Sulfonamide hypersensitivity cross-reactivity (hydrochlorothiazide is a sulfonamide derivative),Acute angle-closure glaucoma (rare with thiazides),Monitor serum electrolytes, renal function, and blood glucose
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
Anuria,Acute or chronic renal insufficiency (creatinine clearance <10 m L/min),Hyperkalemia (serum potassium >5.5 m Eq/L),Concomitant use of other potassium-sparing diuretics, potassium supplements, or amiloride-containing drugs,Hypersensitivity to amiloride, hydrochlorothiazide, or sulfonamide-derived drugs
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) in large amounts. Limit salt intake. Grapefruit juice may increase hydrochlorothiazide absorption; avoid concurrent consumption.
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
First trimester: Limited data; thiazide use associated with possible increased risk of congenital anomalies including neural tube defects and limb reduction defects, but evidence is inconclusive. Second and third trimesters: Hydrochlorothiazide may cause fetal/neonatal electrolyte disturbances, jaundice, and thrombocytopenia. Amiloride has not been associated with major teratogenic effects in animal studies, but human data are inadequate. Overall risk is moderate; avoid in pregnancy if possible, especially for treatment of hypertension, as alternatives exist.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
Hydrochlorothiazide is excreted into breast milk in low amounts (M/P ratio approximately 1.5); amiloride is also excreted in animal milk but human data lacking. Potential for neonatal electrolyte imbalance and thrombocytopenia from thiazide. Use during breastfeeding is not recommended unless essential. Monitor infant for signs of dehydration and electrolyte disturbances.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
No specific dose adjustments recommended for pregnancy due to lack of pharmacokinetic studies; however, increased renal clearance during pregnancy may reduce diuretic efficacy. Caution with hypovolemia and electrolyte disturbances. Use lowest effective dose and consider alternative agents for hypertension in pregnancy (e.g., methyldopa, labetalol).
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
Amiloride is potassium-sparing; hydrochlorothiazide causes potassium loss. The combination offsets hypokalemia risk. Monitor serum potassium, especially in renal impairment or with NSAIDs. Avoid in anuria or severe renal disease. Onset of diuresis: 2 hours; peak effect: 6-12 hours; duration: 24 hours.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,This drug increases urine output and may cause dizziness or lightheadedness; rise slowly from sitting or lying down.,Avoid potassium supplements or salt substitutes containing potassium unless directed by your doctor.,Limit alcohol intake as it can increase dizziness and orthostatic hypotension.,Notify your doctor if you experience muscle cramps, weakness, irregular heartbeat, or excessive thirst.
No interactions on record
"The coadministration of Sulindac, a nonsteroidal anti-inflammatory drug (NSAID), with Chlorothiazide, a thiazide diuretic, may result in a diminished antihypertensive and diuretic effect of Chlorothiazide. Sulindac can inhibit renal prostaglandin synthesis, leading to sodium and water retention, which counteracts the natriuretic and hypotensive actions of Chlorothiazide. This interaction may result in reduced blood pressure control and potentially exacerbate edema in patients with hypertension or heart failure."
"Concomitant use of torasemide, a loop diuretic, and chlorothiazide, a thiazide diuretic, produces synergistic blockade of sodium reabsorption along the nephron, leading to profound diuresis, electrolyte disturbances, and volume depletion. This combination increases the risk of severe hypokalemia, hyponatremia, hypomagnesemia, and metabolic alkalosis, potentially precipitating cardiac arrhythmias, hypotension, or renal impairment, especially in patients with compromised renal function or those on digoxin or antiarrhythmics."
"Flurandrenolide, a topical corticosteroid, can be absorbed systemically and enhance the hypokalemic effect of chlorothiazide, a thiazide diuretic. This interaction occurs through additive potassium-wasting actions: flurandrenolide promotes renal potassium excretion via mineralocorticoid-like effects, while chlorothiazide increases distal tubular potassium loss. Clinically, this can lead to severe hypokalemia, potentially causing cardiac arrhythmias, muscle weakness, and impaired glucose tolerance."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 30 vs AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, answered by our medical review team.
ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is a Thiazide Diuretic that works by Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENa C) in the distal convoluted tubule and collecting duct, inhibiting sodium reabsorption and reducing potassium excretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, increasing sodium, chloride, and water excretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 30 and AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. The standard adult dose of AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is: One tablet (amiloride 5 mg/hydrochlorothiazide 50 mg) orally once daily initially, increased if needed to twice daily. Maximum dose: amiloride 10 mg/hydrochlorothiazide 100 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 30 and AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is classified as Category A/B. First trimester: Limited data; thiazide use associated with possible increased risk of congenital anomalies including neural tube defects and limb reduction defects, but evidence i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.